| Trial ID: | L5099 |
| Source ID: | NCT00551564
|
| Associated Drug: |
Rosiglitazone Maleate
|
| Title: |
Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: rosiglitazone maleate
|
| Outcome Measures: |
Primary: Insulin resistance, baseline and after 8 weeks of Rosiglitazone treatment | Secondary: Insulin resistance, baseline, after 2 weeks treatment, 2 weeks after discontinuation treatment|hepatic glucose output: baseline, after 8 weeks treatment Insulin secretion from oral glucose tolerance, baseline, after 8 weeks treatment|Body composition, baseline & after 8 weeks treatment
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
36
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: DIAGNOSTIC
|
| Start Date: |
2007-07-31
|
| Completion Date: |
2008-09-08
|
| Results First Posted: |
|
| Last Update Posted: |
2017-08-04
|
| Locations: |
GSK Investigational Site, Chula Vista, California, 91911, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00551564
|
